StemGen
↗Milan, Italy
StemGen is a clinical-stage biotechnology company founded in 2006 and based in Milan, Italy. The company specializes in developing innovative differentiation biotherapies for solid tissue cancers by exploiting unique knowledge and technology in cancer stem cell research. StemGen's proprietary approach involves transforming cancer stem cells into normal, mature brain cells as a therapeutic strategy for treating aggressive tumors. The company's scientific foundation was built by renowned neuroscientist Prof. Angelo Luigi Vescovi and focuses on converting cancer stem cells back to a non-tumorigenic state. StemGen has expanded its oncology portfolio from glioblastoma to include colorectal carcinoma research, with a mission to discover and develop effective therapeutics for malignant brain tumors and other solid cancers.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$6.6M (2024)
Founded:2006
Ownership:private
Status:operating
FUNDING
Stage:Clinical Stage
PIPELINE
Stage:Phase 1/Phase 2
Lead Drug Stage:Phase 1 completed, Phase 2 planning
Modalities:Protein therapy, Differentiation therapy, Recombinant proteins
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Academic collaborations with San Raffaele Hospital in Milan (past co-directorship of Stem Cell Research Institute), University of Milan-Bicocca (Angelo Vescovi affiliation), Neural Stem Cells Bank in Terni, Italy
COMPETITION
Position:Niche Player - Early stage, unique differentiation therapy approach
Competitors:Novocure (TTFields for glioblastoma), Apeiron Therapeutics, Denovo Biopharma, Starlight Therapeutics, Plus Therapeutics
LEADERSHIP
Key Executives:
Prof. Angelo Luigi Vescovi - Founder and President
Alberto Visioli - Management/Leadership (LinkedIn profile confirmed)
Scientific Founders:Prof. Angelo Luigi Vescovi, Alessandra Pavesio, Fabrizio Gelain, Maurizio Verga, Brent Allen Reynolds
LINKS
Website:stemgen.net
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with StemGen. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.